Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 31, 2025 | $0.74 | 2025-07-15 | 2025-07-15 |
| April 30, 2025 | $0.74 | 2025-04-15 | 2025-04-15 |
| January 31, 2025 | $0.74 | 2025-01-15 | 2025-01-15 |
| October 31, 2024 | $0.74 | 2024-10-15 | 2024-10-15 |
| July 31, 2024 | $0.74 | 2024-07-15 | 2024-07-15 |
Dividends Summary
- Consistent Payer: has rewarded shareholders with 11 dividend payments over the past 2 years.
- Total Returned Value: Investors who held HROWM shares during this period received a total of $7.76 per share in dividend income.
- Latest Payout: The most recent dividend of $0.74/share was paid 176 days ago, on July 31, 2025.
- Payment Schedule: HROWM currently distributes dividends on a quarterly basis.
- Dividend Growth: Since 2023, the dividend payout has grown by 119.5%, from $0.34 to $0.74.
- Dividend Reliability: HROWM has maintained or increased its dividend for 11 consecutive payments.
Company News
Harrow Inc. announced the acquisition of Melt Pharmaceuticals, a clinical-stage company developing a non-opioid sedation tablet (MELT-300) for medical procedures. The company plans to submit a New Drug Application to the FDA in 2027, targeting a U.S. launch in 2028.
Harrow plans to acquire Melt Pharmaceuticals for its MELT-300 sedation therapy, a non-opioid sublingual medication designed to provide rapid sedation for medical procedures. The acquisition aims to expand Harrow's procedural sedation market presence and offer an alternative to traditional IV sedation.
Harrow is raising $250 million through senior unsecured notes due in 2030, with plans to repay existing debt and potentially fund future business development opportunities.
Harrow is issuing $250 million in senior unsecured notes due 2030 and entering a new $40 million revolving credit facility with Fifth Third Bank. The company plans to use proceeds to repay existing debt and redeem outstanding senior notes.
Pomerantz LLP is investigating potential securities fraud at Harrow, Inc. after the company missed financial estimates in Q1 2025, causing its stock price to drop 4.07%.
